CRMD - CorMedix, Inc.

NYSE American - NYSE American Delayed Price. Currency in USD
6.88
-0.12 (-1.71%)
At close: 4:00PM EDT

6.99 +0.11 (1.60%)
After hours: 5:20PM EDT

Stock chart is not supported by your current browser
Previous Close7.00
Open6.92
Bid0.00 x 1400
Ask0.00 x 1300
Day's Range6.70 - 7.15
52 Week Range0.90 - 13.70
Volume429,436
Avg. Volume685,982
Market Cap163.692M
Beta (3Y Monthly)2.48
PE Ratio (TTM)N/A
EPS (TTM)-1.10
Earnings DateMar 18, 2019 - Mar 22, 2019
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est21.00
Trade prices are not sourced from all markets
  • Thomson Reuters StreetEvents4 days ago

    Edited Transcript of CRMD earnings conference call or presentation 13-May-19 8:30pm GMT

    Q1 2019 CorMedix Inc Earnings Call

  • GlobeNewswire8 days ago

    CorMedix Inc. to Present at the 20th Annual B. Riley FBR Institutional Investor Conference

    BERKELEY HEIGHTS, N.J., May 16, 2019 -- CorMedix Inc. (NYSE American: CRMD), a biopharmaceutical company focused on developing and commercializing therapeutic products for the.

  • CorMedix (CRMD) Reports Q1 Loss, Tops Revenue Estimates
    Zacks11 days ago

    CorMedix (CRMD) Reports Q1 Loss, Tops Revenue Estimates

    CorMedix (CRMD) delivered earnings and revenue surprises of 24.14% and 173.33%, respectively, for the quarter ended March 2019. Do the numbers hold clues to what lies ahead for the stock?

  • Associated Press11 days ago

    CorMedix: 1Q Earnings Snapshot

    The Berkeley Heights, New Jersey-based company said it had a loss of 22 cents per share. The pharmaceutical and medical device company posted revenue of $163,700 in the period. Its adjusted revenue was ...

  • GlobeNewswire11 days ago

    CorMedix Inc. Reports First Quarter 2019 Financial Results and Provides Business Update

    BERKELEY HEIGHTS, N.J., May 13, 2019 -- CorMedix Inc. (NYSE American: CRMD), a biopharmaceutical company focused on developing and commercializing therapeutic products for the.

  • GlobeNewswire14 days ago

    Cormedix Announces Presentation of LOCK-IT-100 Study Results at National Kidney Foundation Spring 2019 Meeting

    The presentation entitled “A Phase III, Prospective, Multicenter, Double-Blind, Active Control Study to Demonstrate the Safety and Effectiveness of Neutrolin® in Preventing Catheter-Related Bloodstream Infections in Subjects Receiving Hemodialysis Therapy as Treatment for End Stage Renal Disease,” is being delivered by Anil Agarwal, M.D. at 10:15 am during the Late-Breaking Presentations.  Dr. Agarwal, who was an investigator in the study, is a Professor of Medicine at The Ohio State University and a consultant to the Company.

  • Should You Take Comfort From Insider Transactions At CorMedix, Inc. (NYSEMKT:CRMD)?
    Simply Wall St.16 days ago

    Should You Take Comfort From Insider Transactions At CorMedix, Inc. (NYSEMKT:CRMD)?

    Want to participate in a short research study? Help shape the future of investing tools and you could win a $250 gift card! It is not uncommon to see companies perform well in the years after insiders buy shares. Unfortunately...

  • GlobeNewswire18 days ago

    CorMedix Inc. to Report First Quarter 2019 Financial Results and Provide a Corporate Update on May 13

    BERKELEY HEIGHTS, N.J., May 06, 2019 -- CorMedix Inc. (NYSE American: CRMD), a biopharmaceutical company focused on developing and commercializing therapeutic products for the.

  • GlobeNewswirelast month

    CorMedix Announces Online Pre-Clinical Abstract at the Upcoming Annual Meeting of American Society of Clinical Oncology

    CorMedix Inc. (NYSE American: CRMD), a biopharmaceutical company focused on developing and commercializing therapeutic products for the prevention and treatment of infectious and inflammatory disease, today announced publication online of a pre-clinical data abstract at the upcoming annual meeting of the American Society of Clinical Oncology (ASCO), a major educational and scientific event in oncology being held in Chicago, IL on May 31 through June 4, 2019. The abstract, entitled "Effective targeted antitumor activity of the antimicrobial agent taurolidine against relapsed/refractory neuroblastoma: Cytotoxicity, target modulation, and tumor xenograft studies", reviews a pre-clinical study in a mouse model of neuroblastoma led by Dr. Aru Narendran, Professor of Pediatrics, Oncology, Biochemistry and Molecular Biology, Cumming School of Medicine, University of Calgary.

  • GlobeNewswirelast month

    CorMedix Completes Sale of $5.4 Million of NOL Tax Benefits Through New Jersey Economic Development Authority Program

    CorMedix Inc. (NYSE American: CRMD), a biopharmaceutical company focused on developing and commercializing therapeutic products for the prevention and treatment of infectious and inflammatory disease, today announced that it has completed the previously announced sale of $5.4 million of NOL tax benefits to two unrelated, profitable New Jersey corporations through the New Jersey Economic Development Authority’s New Jersey Technology Business Tax Certificate Transfer program for State Fiscal Year 2018. “We are pleased to have closed on this transaction,” said Khoso Baluch, CorMedix CEO. The New Jersey Technology Business Tax Certificate Transfer (NOL) program enables qualified, unprofitable NJ-based technology or biotechnology companies with fewer than 225 U.S. employees (including parent company and all subsidiaries) to sell a percentage of net operating losses and research and development (R&D) tax credits to unrelated profitable corporations.

  • ACCESSWIRElast month

    CorMedix Notified of Compliance with NYSE American Listing Requirements

    BERKELEY HEIGHTS, NJ / ACCESSWIRE / April 11, 2019 / CorMedix Inc. (NYSE American: CRMD), a biopharmaceutical company focused on developing and commercializing therapeutic products for the prevention and treatment of infectious and inflammatory disease, today announced that on Friday, April 5, 2019, the NYSE American notified CorMedix that the company had regained compliance with the NYSE American listing requirements because the company has resolved the continued listing deficiency with respect to Section 1003(a)(i), Section 1003(a)(ii) and Section 1003(a)(iii) of the NYSE American Company Guide.

  • Is CorMedix, Inc. (NYSEMKT:CRMD) Overpaying Its CEO?
    Simply Wall St.2 months ago

    Is CorMedix, Inc. (NYSEMKT:CRMD) Overpaying Its CEO?

    Want to participate in a research study? Help shape the future of investing tools and earn a $60 gift card! In 2016 Khoso Baluch was appointed CEO of CorMedix, Inc. (NYSEMKT:CRMD). This analysis aims first to contrast CEO...

  • Benzinga2 months ago

    The Daily Biotech Pulse: Japanese Cheer For AbbVie, Myokardia Offering, CytomX CFO Departs

    Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech stocks hitting 52-week highs on March 25) Axsome Therapeutics Inc (NASDAQ: AXSM ) Catalyst Pharmaceuticals ...

  • ACCESSWIRE2 months ago

    CorMedix Confirms Previously Announced One-For-Five Reverse Stock Split

    BERKELEY HEIGHTS, NJ / ACCESSWIRE / March 25, 2019 / CorMedix Inc. (NYSE American: CRMD), a biopharmaceutical company focused on developing and commercializing therapeutic products for the prevention and treatment of infectious and inflammatory disease, today confirmed that the previously announced one-for-five reverse stock split of the Company's common stock, par value $0.001, will be effective at 9:00 am Eastern Time tomorrow, March 26. The Company's common stock will trade on the NYSE American on a split-adjusted basis under a new CUSIP number, 21900C308, beginning on March 26, 2019. Khoso Baluch, CorMedix CEO commented, "We are implementing the reverse stock split as planned so that we have flexibility to take advantage of future investment opportunities, to possibly attract more institutional interest into our stock, and given our need to have available unissued shares to reserve for past transactions.

  • ACCESSWIRE2 months ago

    CorMedix Inc. Announces Appointment of Phoebe Mounts as Executive Vice President and General Counsel

    BERKELEY HEIGHTS, NJ / ACCESSWIRE / March 21, 2019 / CorMedix Inc. (NYSE American: CRMD), a biopharmaceutical company focused on developing and commercializing therapeutic products for the prevention and treatment of infectious and inflammatory disease, today announced the appointment of Dr. Phoebe Mounts, Esq. Dr. Mounts, currently a partner at the law firm Morgan Lewis, will head up the Company's legal, compliance and regulatory affairs.

  • ACCESSWIRE2 months ago

    CorMedix Inc. Reports Fourth Quarter And Full-Year 2018 Financial Results, Announces Reverse Stock Split And Provides Business Update

    Conference Call Scheduled for Today at 4:30 p.m. Eastern Time BERKELEY HEIGHTS, NJ / ACCESSWIRE / March 14, 2019 / CorMedix Inc. (NYSE American: CRMD), a biopharmaceutical company focused on developing ...

  • ACCESSWIRE2 months ago

    CorMedix Inc. to Present at Roth and Oppenheimer & Co. Investor Conferences

    BERKELEY HEIGHTS, NJ / ACCESSWIRE / March 11, 2019 / CorMedix Inc. (NYSE American: CRMD), a biopharmaceutical company focused on developing and commercializing therapeutic products for the prevention and ...

  • Will CorMedix (CRMD) Report Negative Q4 Earnings? What You Should Know
    Zacks2 months ago

    Will CorMedix (CRMD) Report Negative Q4 Earnings? What You Should Know

    CorMedix (CRMD) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

  • ACCESSWIRE3 months ago

    CorMedix Inc. to Report Year Ended December 31, 2018 Financial Results on Thursday, March 14

    BERKELEY HEIGHTS, NJ / ACCESSWIRE / March 7, 2019 / CorMedix Inc. (NYSE American: CRMD), a biopharmaceutical company focused on developing and commercializing therapeutic products for the prevention and ...

  • ACCESSWIRE3 months ago

    CorMedix Inc. Appoints Alan W. Dunton, M.D. to Board of Directors

    BERKELEY HEIGHTS, NJ / ACCESSWIRE / March 4, 2019 / CorMedix Inc. (NYSE American: CRMD), a biopharmaceutical company focused on developing and commercializing therapeutic products for the prevention and treatment of infectious and inflammatory disease, today announced that Alan W. Dunton, M.D. has been appointed unanimously to the Company's Board of Directors. Dr. Dunton becomes the sixth member of the Company's Board, filling a vacant seat previously occupied by Gary Gelbfish, M.D., who resigned in January 2019. Khoso Baluch, CorMedix Chief Executive Officer stated, "I am excited to have Alan join the board of CorMedix.

  • GlobeNewswire3 months ago

    Research Report Identifies SS&C Technologies, Allergan plc, CorMedix, The Allstate, Vedanta, and Lexicon Pharmaceuticals with Renewed Outlook — Fundamental Analysis, Calculating Forward Movement

    NEW YORK, Feb. 21, 2019 -- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors,.

  • ACCESSWIRE3 months ago

    Biotech Bounce Just Getting Started

    HENDERSON, NV / ACCESSWIRE / February 20, 2019 / Biotech may have had a hard 2018, but the sector is making up for lost time at the start of this year. This may be just getting started as many fund managers ...

  • Here's Why CorMedix Dropped as Much as 27.1% Today
    Motley Fool3 months ago

    Here's Why CorMedix Dropped as Much as 27.1% Today

    The company announced an update after meeting the FDA.

  • ACCESSWIRE3 months ago

    CorMedix Inc. Announces FDA Meeting Update

    BERKELEY HEIGHTS, NJ / ACCESSWIRE / February 14, 2019 / CorMedix Inc. (NYSE American: CRMD), a biopharmaceutical company focused on developing and commercializing therapeutic products for the prevention and treatment of infectious and inflammatory disease, today announced that it has begun discussions with the U.S. FDA regarding its recently completed and unblinded Phase 3 LOCK-IT-100 study to support regulatory approval for Neutrolin®, the Company's investigational product under development as a catheter lock solution for patients suffering from end stage renal disease undergoing hemodialysis. At the meeting, the FDA agreed that the Company could request consideration of Neutrolin for approval under the LPAD (Limited Population Pathway for Antibacterial and Antifungal Drugs) pathway. Data originally submitted to the FDA included preliminary analyses from 653 subjects at the time of the interim analysis, including the first 28 cases of catheter-related blood stream infection (CRBSI).

  • ACCESSWIRE3 months ago

    Biotech and Cannabis Stocks That Are Emerging

    HENDERSON, NV / ACCESSWIRE / February 13, 2019 / One you should research right away, BioRestorative Therapies, Inc. (BRTX) , a life sciences company focused on stem cell-based therapies, is developing ...